Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Japan Drug Majors Expand Global Oncology Sales in FY2021
May 30, 2022
-
BUSINESS Moderna Eyes Bivalent Booster Rollout This Fall via Emergency Approval Path in Japan: CMO
May 30, 2022
-
BUSINESS AstraZeneca Tops Foreign Pharma Ranking in 2021, Pfizer Sales Undisclosed: Jiho
May 27, 2022
-
REGULATORY Japan Approves Additional Indications, Dosages for Rinvoq, Adcetris, Rozex, and More
May 27, 2022
-
BUSINESS Top 4 Wholesalers Log 62% Rise in Operating Profit in FY2021 on Rebound in Doctor Visits
May 27, 2022
-
BUSINESS Sandoz Japan on Hunt for Biosimilar In-Licensing, Sales Tie-Ups after Avastin Deal
May 26, 2022
-
BUSINESS Japan Pharma Market Up 3.3% in FY2021, Opdivo Rises to No.1: IQVIA
May 26, 2022
-
REGULATORY MOF Panel Nudges Full Annual Drug Re-Pricing, Phase-Out for 2% Buffer Zone
May 26, 2022
-
BUSINESS Vabysmo, Ondexxya, Ozempic 2 mg Pen Now Available in Japan
May 26, 2022
-
BUSINESS Novavax Vaccine Officially Added to Japan’s Free COVID-19 Inoculation Program
May 26, 2022
-
BUSINESS BMS CEO Sees Faster Drug Development as Industry Imperative after COVID Vaccine Feat
May 25, 2022
-
BUSINESS US Business Made or Broke FY2021 Earnings of Big 3 Generic Makers; Nichi-Iko, Sawai Suffer Losses
May 24, 2022
-
REGULATORY 2 mg Pen of Supply-Crippled Ozempic, 3rd Avastin Biosimilar Get Japan Listing
May 24, 2022
-
REGULATORY Japan’s Emergency Approval System Comes into Force, Nod Based on Presumed Efficacy
May 23, 2022
-
REGULATORY MOF Budget Examiner Presses for “Full” Annual Re-Pricing, Stepwise Cut in 2% Buffer Zone If No Reasonable Basis Given
May 20, 2022
-
REGULATORY Chuikyo OKs Listing of 14 Drugs on May 25, Biggest Peak Sales Forecast for Vabysmo
May 19, 2022
-
REGULATORY 4 Drugs Face Zero Premium Rule for Low Cost Disclosures: May Price Listing
May 19, 2022
-
BUSINESS Argenx CEO Sees Big Potential for Vyvgart with 100-Plus Diseases Driven by IgGs; Analysts Peg Peak Sales at US$5-10 Billion
May 18, 2022
-
BUSINESS AstraZeneca Ranks Third in Japan Sales Ranking with 12.1% Growth, Good Start in Q1 Too
May 18, 2022
-
ORGANIZATION PhRMA Urges Japan to Exclude Patented Products from Off-Year Re-Pricing in 2023, Create Innovation Ecosystem
May 17, 2022
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…